Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of rilapladib in Alzheimer's disease with cerebrovascular disease
2010-020993-41Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of rilapladib in Alzheimer's disease (AD), sponsored by GSK. Primary endpoints: Change from baseline in CSF Aβ42 at Week 24, Change from baseline in CSF Aβ40 at Week 24 and 1 more. Started Apr 2011; status: completed.
02
Drugs
rilapladib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-020993-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020993-41.